WASHINGTON—The use of glucagon-like peptide-1 receptor agonists has exploded over the past year, mainly because of their powerful anti-obesity effects, but this growth has raised concerns about potential adverse events during GI procedures. Experts discussed these concerns and presented the latest recommendations for endoscopists managing patients taking these medications at DDW 2024.
“This explosion in use has led to tremendous chaos in endoscopy—trying to navigate these new